| Literature DB >> 25288194 |
Yogendra Kumar Gupta1, Arun Kumar Pradhan, Aman Goyal, Prafull Mohan.
Abstract
Clinical research, including clinical trials, is the bedrock of evidence-based medicine and is the most reliable method of generating credible data. Over the last decade, India has been one of the preferred destinations for clinical research activities. However, a couple of trials generated widespread media coverage due to alleged ethical transgressions, which generated debate among various stakeholders and dented the overall image of clinical research activities in the country. One of the major issues which has emerged is of compensation to research participants for clinical trial-related injury or death. To address this question, the Government of India has come up with regulations regarding compensation for research participants. While these rules provide a robust framework for compensation, some concerns have been raised regarding interpretation and implementation of these guidelines. In this article, we have tried to raise some debatable issues that need to be addressed to bring more clarity to this subject. These issues need to be handled in a balanced manner so that they are able to address the concerns of all stakeholders. It is envisaged that once clarity emerges, confidence in the clinical research process will be restored.Entities:
Mesh:
Year: 2014 PMID: 25288194 DOI: 10.1007/s40264-014-0230-3
Source DB: PubMed Journal: Drug Saf ISSN: 0114-5916 Impact factor: 5.606